These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1526 related items for PubMed ID: 22111124

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Sustained release methylphenidate for the treatment of ADHD in amphetamine abusers: a pilot study.
    Konstenius M, Jayaram-Lindström N, Beck O, Franck J.
    Drug Alcohol Depend; 2010 Apr 01; 108(1-2):130-3. PubMed ID: 20015599
    [Abstract] [Full Text] [Related]

  • 4. Long-acting methylphenidate reduces collision rates of young adult drivers with attention-deficit/hyperactivity disorder.
    Cox DJ, Davis M, Mikami AY, Singh H, Merkel RL, Burket R.
    J Clin Psychopharmacol; 2012 Apr 01; 32(2):225-30. PubMed ID: 22367664
    [Abstract] [Full Text] [Related]

  • 5. Twenty-four-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD.
    Rösler M, Retz W, Fischer R, Ose C, Alm B, Deckert J, Philipsen A, Herpertz S, Ammer R.
    World J Biol Psychiatry; 2010 Aug 01; 11(5):709-18. PubMed ID: 20353312
    [Abstract] [Full Text] [Related]

  • 6. Predictors of placebo response in adults with attention-deficit/hyperactivity disorder: data from 2 randomized trials of osmotic-release oral system methylphenidate.
    Buitelaar JK, Sobanski E, Stieglitz RD, Dejonckheere J, Waechter S, Schäuble B.
    J Clin Psychiatry; 2012 Aug 01; 73(8):1097-102. PubMed ID: 22780962
    [Abstract] [Full Text] [Related]

  • 7. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.
    Fallu A, Richard C, Prinzo R, Binder C.
    Curr Med Res Opin; 2006 Dec 01; 22(12):2557-66. PubMed ID: 17166338
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
    Chou WJ, Chou MC, Tzang RF, Hsu YC, Gau SS, Chen SJ, Wu YY, Huang YF, Liang HY, Cheng H.
    Psychiatry Clin Neurosci; 2009 Apr 01; 63(2):167-75. PubMed ID: 19335386
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Clinical and cognitive response to extended-release methylphenidate (Medikinet) in attention deficit/hyperactivity disorder: efficacy evaluation.
    Fernández-Jaén A, Fernández-Mayoralas DM, Pardos A, Calleja-Pérez B, Muñoz Jareño N.
    Adv Ther; 2009 Dec 01; 26(12):1097-110. PubMed ID: 20082241
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
    Findling RL.
    Clin Ther; 2008 May 01; 30(5):942-57. PubMed ID: 18555941
    [Abstract] [Full Text] [Related]

  • 14. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder.
    Wilens TE, McBurnett K, Bukstein O, McGough J, Greenhill L, Lerner M, Stein MA, Conners CK, Duby J, Newcorn J, Bailey CE, Kratochvil CJ, Coury D, Casat C, Denisco MJ, Halstead P, Bloom L, Zimmerman BA, Gu J, Cooper KM, Lynch JM.
    Arch Pediatr Adolesc Med; 2006 Jan 01; 160(1):82-90. PubMed ID: 16389216
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
    Cox DJ, Merkel RL, Moore M, Thorndike F, Muller C, Kovatchev B.
    Pediatrics; 2006 Sep 01; 118(3):e704-10. PubMed ID: 16950962
    [Abstract] [Full Text] [Related]

  • 17. Attention-deficit-hyperactivity disorder: an update.
    Dopheide JA, Pliszka SR.
    Pharmacotherapy; 2009 Jun 01; 29(6):656-79. PubMed ID: 19476419
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder.
    Spencer TJ, Adler LA, McGough JJ, Muniz R, Jiang H, Pestreich L, Adult ADHD Research Group.
    Biol Psychiatry; 2007 Jun 15; 61(12):1380-7. PubMed ID: 17137560
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
    Chavez B, Sopko MA, Ehret MJ, Paulino RE, Goldberg KR, Angstadt K, Bogart GT.
    Ann Pharmacother; 2009 Jun 15; 43(6):1084-95. PubMed ID: 19470858
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 77.